After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight ...

Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

With shortages of its blockbuster obesity now declared resolved in the USA, Denmark’s Novo Nordisk (NOV: N) is moving to make ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients ... This includes 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg dose strengths.

Wegovy and Zepbound are part of a GLP-1 class of treatments that has shown unprecedented results for helping people shed weight by decreasing appetite and boosting feelings of fullness.

can receive Wegovy (2.5mg, 0.5mg, 1mg, 1.7mg, and 2.4mg) at a reduced cost of $499 per month. According to the Company, the program will also provide benefit verification, refill reminders ...